The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia
The addition of targeted therapies, including BCR::ABL1 tyrosine kinase inhibitors and CD19/CD22-directed immunotherapies, has improved long‑term survival rates in adult B‑cell ALL to 70–90%.
The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Basic research and genomic mapping have identified new prognostic biomarkers, targets, and ALL subtypes (e.g., Philadelphia‑like ALL). The ongoing therapeutic revolution in ALL is driven by the addition to the treatment arsenal of therapies that target the ABL fusions like the BCR::ABL1 tyrosine kinase inhibitors as well as novel agents that target CD19 and CD22: the CD22 antibody‑drug conjugate inotuzumab ozogamicin, the bispecific CD3‑CD19 T‑cell engager (BiTE) antibody blinatumomab, and CD19 chimeric antigen receptor T‑cell therapies. These combinations have improved the long‑term survival rates in B‑cell ALL to 70%, and in Philadelphia chromosome‑positive ALL to 80–90%. The desired goals are to achieve cure rates comparable to pediatric ALL and reduce or eliminate the need for prolonged intensive/maintenance chemotherapy and associated toxicities.
The introduction of targeted agents and cellular therapies has dramatically increased survival in adult B‑cell ALL, bringing rates closer to those seen in children and offering less toxic, more sustainable treatment options. This paradigm shift promises to improve long‑term outcomes and reduce treatment‑related morbidity in an otherwise historically poor‑prognosis disease.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)